Plasma thrombin activatable fibrinolysis inhibitor levels in Behçet's disease

Turkish Journal of Medical Sciences

Volumn 37, Issue 5, 2007, Pages 267-271

  Özcan, Mehmet Ali ^a   Akar, Servet ^a   Alacacioǧlu, Inci ^a   Pişkin, Özden ^a   Yüksel, Faize ^a   Gürler, Oǧuz ^a   Akkoç, Nurullah ^a   Demirkan, Fatih ^a   Özsan, Güer Hayri ^a   Özkan, Şebnem ^a   Önen, Fatoş ^a   Ündar, Bülent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Coagulation; Fibrinolysis; TAFI

Indexed keywords

ANTIBODIES; COAGULATION; PATHOGENS; PATIENT TREATMENT; PLASMA (HUMAN); STATISTICAL METHODS;

FIBRINOLYSIS INHIBITOR; PATHOGENESIS; PLASMIN GENERATION;

ENZYME INHIBITION;

ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMOPHILIA; HUMAN; MALE; RISK FACTOR;

EID: 35648945255     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S et al. Vascular involvement in Behcet's disease. J Rheumatol 1992; 19: 402-410.
2. Aydintug AO, Tokgöz G, D'Cruz DP, Gurler A, Cervera R, Duzgun N et al. Antibodies to endothelial cells in patients with Behcet's disease. Clin Immunopathol 1993; 67: 157-162.
3. Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB et al. Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res 2002; 106: 19-24.
4. Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G et al. Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 1984; 43: 746-748.
5. Chafa O, Fischer AM, Meriane F, Chellali T, Stenberg C, Otmani F et al. Behcet's syndrome associated with protein S deficiency. Thromb Haemost 1992; 67: 1-3.
6. Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behcet's disease. Thromb Res 1997; 86: 197-204.
7. Mammo L, Al-Dalaan A, Bahabri SS, Saour JN. Association of factor V Leiden with Behcet's disease. J Rheumatol 1997; 24: 2196-2198.
8. Mader R, Ziv M, Adawi M, Mader R, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999; 26: 2404-2408.
9. Vaya A, Forner MJ, Estelles A, Villa P, Mira Y, Ferrando F et al. Intracardiac thrombosis in a case of Behcet's disease associated with the prothrombin 20210G-A mutation. Haematologica 2000; 85: 425-428.
10. Oner AF, Gurgey A, Gurler A, Mesci L. Factor V Leiden mutation in patients with Behcet's disease. J Rheumatol 1998; 25: 496-498.
11. Toydemir PB, Elhan AH, Tukun A, Toydemir R, Gurler A, Tuzuner A et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Behcet's disease. J Rheumatol 2000; 27: 2849-2854.
12. Mishima H, Masuda K, Shimada S, Toki N, Tsushima H, Gocho M. Plasminogen activator activity levels in patients with Behcet's syndrome. Arch Ophthalmol 1985; 103: 935-936.
13. Mosnier LO, von dem Borne P, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
14. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y. Insulin resistance is associated with increased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
15. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
16. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368.
17. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activatable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 59-74.
18. Bouma BN, Meijers J. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol 2004; 41(Suppl 1): 13-19.
19. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). 1566-1574.
20. Alacacioglu I, Ozcan MA, Alacacioglu A, Polat M, Yuksel F, Demirkan F et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 2004; 114: 155-159.
21. Nalcaci M, Pekcelen Y. Antithrombin II, protein C and protein S levels in patients with Behcet's disease. J Int Med Res. 1998; 26(4): 206-208.
22. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, López-Soto A et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002; 112(1): 37-43.
23. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB et al. Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res 2005; 115: 287-292.